Ai‐Ming Yu

8.7k total citations · 3 hit papers
159 papers, 6.8k citations indexed

About

Ai‐Ming Yu is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Ai‐Ming Yu has authored 159 papers receiving a total of 6.8k indexed citations (citations by other indexed papers that have themselves been cited), including 94 papers in Molecular Biology, 53 papers in Cancer Research and 45 papers in Oncology. Recurrent topics in Ai‐Ming Yu's work include MicroRNA in disease regulation (42 papers), RNA Interference and Gene Delivery (36 papers) and RNA modifications and cancer (36 papers). Ai‐Ming Yu is often cited by papers focused on MicroRNA in disease regulation (42 papers), RNA Interference and Gene Delivery (36 papers) and RNA modifications and cancer (36 papers). Ai‐Ming Yu collaborates with scholars based in United States, China and Switzerland. Ai‐Ming Yu's co-authors include Frank J. Gonzalez, Young Hee Choi, Mei‐Juan Tu, Jeffrey R. Idle, Kristopher W. Krausz, Robert L. Haining, A Küpfer, Gavin M. Traber, Pui Yan Ho and Marilyn E. Morris and has published in prestigious journals such as Nucleic Acids Research, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Ai‐Ming Yu

150 papers receiving 6.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development

2014 451 citations Ai‐Ming Yu et al. profile →
RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges

2020 268 citations Ai‐Ming Yu, Mei‐Juan Tu et al. profile →
RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies

2022 176 citations Gavin M. Traber, Ai‐Ming Yu Journal of Pharmacology and Experimental Therapeutics profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Ai‐Ming Yu	3.8k	1.9k	1.6k	1.6k	384	159	6.8k
Xinxin Ding	2.6k 0.7×	917 0.5×	1.5k 1.0×	3.1k 2.0×	411 1.1×	210	6.7k
David W. Hein	6.0k 1.6×	3.3k 1.7×	1.3k 0.8×	1.3k 0.8×	571 1.5×	280	10.1k
Curtis J. Omiecinski	2.5k 0.7×	836 0.4×	1.2k 0.8×	2.8k 1.8×	608 1.6×	117	7.5k
Kenneth K. Chan	5.0k 1.3×	1.5k 0.8×	1.3k 0.9×	387 0.2×	377 1.0×	172	8.1k
Kiyoshi Nagata	2.5k 0.7×	535 0.3×	1.5k 1.0×	2.7k 1.7×	279 0.7×	231	6.6k
Christopher E. Goldring	3.8k 1.0×	814 0.4×	743 0.5×	1.5k 1.0×	275 0.7×	124	7.1k
Ryuichi Kato	4.3k 1.1×	740 0.4×	811 0.5×	895 0.6×	264 0.7×	272	7.8k
Yong‐Yeon Cho	5.1k 1.3×	1.0k 0.5×	1.5k 0.9×	474 0.3×	578 1.5×	268	8.6k
Denis M. Grant	2.9k 0.8×	1.4k 0.7×	831 0.5×	1.2k 0.8×	567 1.5×	90	5.3k
Cheng Huang	4.4k 1.2×	1.3k 0.7×	1.2k 0.7×	632 0.4×	555 1.4×	263	8.8k

Countries citing papers authored by Ai‐Ming Yu

Since Specialization

Citations

This map shows the geographic impact of Ai‐Ming Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ai‐Ming Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ai‐Ming Yu more than expected).

Fields of papers citing papers by Ai‐Ming Yu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ai‐Ming Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ai‐Ming Yu. The network helps show where Ai‐Ming Yu may publish in the future.

Co-authorship network of co-authors of Ai‐Ming Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Ai‐Ming Yu. A scholar is included among the top collaborators of Ai‐Ming Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ai‐Ming Yu. Ai‐Ming Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tu, Mei‐Juan, et al.. (2025). Practical Pharmacokinetic–Pharmacodynamic Models in Oncology. Pharmaceutics. 17(11). 1452–1452.

Tang, Bufu, Wen Zhang, Yongjie Zhou, et al.. (2025). Sequential HAIC-TACE combined with targeted and immunotherapy in hepatocellular carcinoma: a quality improvement study. International Journal of Surgery. 111(10). 6942–6960.

Zhang, Xiong, Yang Yang, Xingling Zheng, et al.. (2025). Effective therapeutic targeting of tumor lineage plasticity in neuroendocrine prostate cancer by BRD4 inhibitors. Acta Pharmaceutica Sinica B. 15(3). 1415–1429. 2 indexed citations

Tang, Bufu, Ai‐Ming Yu, Ruiqi Liu, et al.. (2025). Immune checkpoint inhibitor‐induced vitiligo: A large‐scale real world pharmacovigilance study. International Journal of Cancer. 158(3). 738–751.

Zhang, Jiale, et al.. (2024). Derivation of ecological safety thresholds and risk assessment of new SDHI fungicides in farmland system. The Science of The Total Environment. 954. 176773–176773. 3 indexed citations

Wang, Yimei, Mei‐Juan Tu, & Ai‐Ming Yu. (2024). Efflux ABC transporters in drug disposition and their posttranscriptional gene regulation by microRNAs. Frontiers in Pharmacology. 15. 1423416–1423416. 7 indexed citations

Ning, Shu, Wei Lou, Alan P. Lombard, et al.. (2024). PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells. Cancer Research Communications. 4(11). 2976–2985.

Luo, Zhangyi, Yixian Huang, Neelu Batra, et al.. (2024). Inhibition of iRhom1 by CD44-targeting nanocarrier for improved cancer immunochemotherapy. Nature Communications. 15(1). 255–255. 30 indexed citations

Traber, Gavin M., et al.. (2024). Novel RNA molecular bioengineering technology efficiently produces functional miRNA agents. RNA. 30(6). rna.079904.123–rna.079904.123. 6 indexed citations

10.

Tu, Mei‐Juan, Mei‐Juan Tu, & Ai‐Ming Yu. (2023). Recent Advances in Novel Recombinant RNAs for Studying Post-transcriptionalGene Regulation in Drug Metabolism and Disposition. Current Drug Metabolism. 24(3). 175–189.

11.

Ning, Shu, Chengfei Liu, Wei Lou, et al.. (2022). Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide Treatment. Molecular Cancer Therapeutics. 21(10). 1594–1607. 16 indexed citations

12.

Zimmermann, Maike, Tao Li, Thomas J. Semrad, et al.. (2020). Oxaliplatin–DNA Adducts as Predictive Biomarkers of FOLFOX Response in Colorectal Cancer: A Potential Treatment Optimization Strategy. Molecular Cancer Therapeutics. 19(4). 1070–1079. 20 indexed citations

13.

Jilek, Joseph L., Mei‐Juan Tu, Chao Zhang, & Ai‐Ming Yu. (2020). Pharmacokinetic and Pharmacodynamic Factors Contribute to Synergism between Let-7c-5p and 5-Fluorouracil in Inhibiting Hepatocellular Carcinoma Cell Viability. Drug Metabolism and Disposition. 48(12). 1257–1263. 19 indexed citations

14.

Li, Daifeng, Ying Yuan, Mei‐Juan Tu, et al.. (2020). The Optimal Outcome of Suppressing Ewing Sarcoma Growth in vivo With Biocompatible Bioengineered miR-34a-5p Prodrug. Frontiers in Oncology. 10. 222–222. 5 indexed citations

15.

Simion, Catalina, Neelu Batra, Anastasia L. Berg, et al.. (2019). A Novel Bioengineered miR-127 Prodrug Suppresses the Growth and Metastatic Potential of Triple-Negative Breast Cancer Cells. Cancer Research. 80(3). 418–429. 49 indexed citations

16.

Tian, Ye, et al.. (2018). Bioengineered miR-27b-3p and miR-328-3p modulate drug metabolism and disposition via the regulation of target ADME gene expression. Acta Pharmaceutica Sinica B. 9(3). 639–647. 56 indexed citations

17.

Yu, Ai‐Ming, et al.. (2018). RNA therapy: Are we using the right molecules?. Pharmacology & Therapeutics. 196. 91–104. 120 indexed citations

18.

Ho, Pui Yan, Zhijian Duan, Neelu Batra, et al.. (2018). Bioengineered Noncoding RNAs Selectively Change Cellular miRNome Profiles for Cancer Therapy. Journal of Pharmacology and Experimental Therapeutics. 365(3). 494–506. 52 indexed citations

19.

Zhou, Amy, et al.. (2013). Small Nucleolar RNA-Derived MicroRNA hsa-miR-1291 Modulates Cellular Drug Disposition through Direct Targeting of ABC Transporter ABCC1. Drug Metabolism and Disposition. 41(10). 1744–1751. 71 indexed citations

20.

Vieira, Ana Paula Miranda, et al.. (2010). In vivo Silk Fibroin Biocompatibility. Investigative Ophthalmology & Visual Science. 51(13). 4872–4872. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact